• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cirrhosis in Wilson Disease is characterized by Impaired Hepatic Synthesis, Leukopenia and Thrombocytopenia.Wilson 病的肝硬化特征为肝脏合成受损、白细胞减少和血小板减少。
Int J Med Sci. 2020 May 29;17(10):1345-1350. doi: 10.7150/ijms.44338. eCollection 2020.
2
Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis.Wilson 病相关性肝硬化与乙型肝炎相关性肝硬化的肝脏特征差异。
World J Gastroenterol. 2019 Jan 21;25(3):378-387. doi: 10.3748/wjg.v25.i3.378.
3
[Progress in the diagnosis and treatment of idiopathic non-cirrhotic portal hypertension].[特发性非肝硬化性门静脉高压症的诊断与治疗进展]
Zhonghua Gan Zang Bing Za Zhi. 2021 Jan 20;29(1):87-91. doi: 10.3760/cma.j.cn501113-20191201-00439.
4
Analysis of clinical and biochemical spectrum of Wilson disease patients.肝豆状核变性患者的临床及生化特征分析
Indian J Pathol Microbiol. 2012 Jul-Sep;55(3):365-9. doi: 10.4103/0377-4929.101746.
5
[Clinicopathological features of Wilson disease: report of 29 cases].[肝豆状核变性的临床病理特征:29例报告]
Zhonghua Yi Xue Za Zhi. 2013 May 14;93(18):1422-5.
6
Anemia Is Associated with Disease Severity, Hepatic Complications, and Progression of Wilson Disease: A Retrospective Cohort Study.贫血与威尔逊病的疾病严重程度、肝脏并发症和疾病进展相关:一项回顾性队列研究。
Dig Dis. 2023;41(4):632-640. doi: 10.1159/000530473. Epub 2023 Apr 5.
7
Distinguishing between the complications of Wilson disease-related cirrhosis and HBV-related cirrhosis.区分肝豆状核变性相关肝硬化和乙肝相关肝硬化的并发症。
Curr Med Res Opin. 2022 Jan;38(1):75-81. doi: 10.1080/03007995.2021.1993160. Epub 2021 Oct 24.
8
Effect of laparoscopic splenectomy on portal haemodynamics in patients with liver cirrhosis and portal hypertension.腹腔镜脾切除术对肝硬化门脉高压患者门静脉血流动力学的影响。
Br J Surg. 2014 Nov;101(12):1585-93. doi: 10.1002/bjs.9622. Epub 2014 Sep 9.
9
Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting.威尔逊病:加拿大对成人门诊环境中临床表现及治疗结果的观点
Can J Gastroenterol. 2012 Jun;26(6):333-9. doi: 10.1155/2012/123431.
10
Clinical, laboratory, and hemodynamic parameters in portal hypertensive gastropathy: a study of 254 cirrhotics.门脉高压性胃病的临床、实验室和血液动力学参数:254 例肝硬化患者的研究。
J Clin Gastroenterol. 2010 Apr;44(4):294-300. doi: 10.1097/MCG.0b013e3181b37ea1.

引用本文的文献

1
A single-cell transcriptomic atlas of immune cells in Wilson disease identifies copper-specific immune regulation.威尔逊病免疫细胞的单细胞转录组图谱揭示了铜特异性免疫调节。
iScience. 2025 Apr 17;28(5):112450. doi: 10.1016/j.isci.2025.112450. eCollection 2025 May 16.
2
Plant-derived chelators and ionophores as potential therapeutics for metabolic diseases.植物来源的螯合剂和离子载体作为代谢疾病的潜在治疗方法。
Chem Soc Rev. 2023 Jun 6;52(11):3927-3945. doi: 10.1039/d3cs00167a.
3
Addressing the Challenges in the Diagnosis and Management of Pediatric Wilson's Disease-Case Report and Literature Review.解决儿童威尔逊病诊断和管理中的挑战-病例报告和文献复习。
Medicina (Kaunas). 2023 Apr 18;59(4):786. doi: 10.3390/medicina59040786.
4
Serum fetuin-A is decreased in cirrhotic patients with Wilson's disease.肝硬化伴 Wilson 病患者血清胎球蛋白 A 降低。
PLoS One. 2023 Mar 7;18(3):e0282801. doi: 10.1371/journal.pone.0282801. eCollection 2023.
5
Differences in complications between hepatitis B-related cirrhosis and alcohol-related cirrhosis.乙型肝炎相关性肝硬化和酒精性肝硬化在并发症方面的差异。
Open Med (Wars). 2021 Dec 6;17(1):46-52. doi: 10.1515/med-2021-0401. eCollection 2022.
6
Wilson's Disease: An Update on the Diagnostic Workup and Management.威尔逊氏病:诊断检查与管理的最新进展
J Clin Med. 2021 Oct 30;10(21):5097. doi: 10.3390/jcm10215097.

本文引用的文献

1
Liver pathology in Wilson's disease: From copper overload to cirrhosis.Wilson 病的肝脏病理学:从铜过载到肝硬化。
J Inorg Biochem. 2019 Apr;193:106-111. doi: 10.1016/j.jinorgbio.2019.01.008. Epub 2019 Jan 15.
2
Differential hepatic features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated cirrhosis.Wilson 病相关性肝硬化与乙型肝炎相关性肝硬化的肝脏特征差异。
World J Gastroenterol. 2019 Jan 21;25(3):378-387. doi: 10.3748/wjg.v25.i3.378.
3
Beyond a Measure of Liver Function-Bilirubin Acts as a Potential Cardiovascular Protector in Chronic Kidney Disease Patients.肝功能之外的指标-胆红素在慢性肾脏病患者中可作为潜在的心血管保护因子。
Int J Mol Sci. 2018 Dec 29;20(1):117. doi: 10.3390/ijms20010117.
4
Burden of liver diseases in the world.世界范围内的肝脏疾病负担。
J Hepatol. 2019 Jan;70(1):151-171. doi: 10.1016/j.jhep.2018.09.014. Epub 2018 Sep 26.
5
Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease.年龄和性别而非 ATP7B 基因型有效影响威尔逊病的临床表型。
Hepatology. 2019 Apr;69(4):1464-1476. doi: 10.1002/hep.30280. Epub 2019 Mar 1.
6
Wilson disease.肝豆状核变性
Nat Rev Dis Primers. 2018 Sep 6;4(1):21. doi: 10.1038/s41572-018-0018-3.
7
Non-Invasive Predictors of Gastro-Oesophageal Varices.胃食管静脉曲张的非侵入性预测指标
JNMA J Nepal Med Assoc. 2017 Jul-Sep;56(207):298-303.
8
Clinical states of cirrhosis and competing risks.肝硬化的临床状态和竞争风险。
J Hepatol. 2018 Mar;68(3):563-576. doi: 10.1016/j.jhep.2017.10.020. Epub 2017 Oct 27.
9
Management of ascites and hepatorenal syndrome.腹水和肝肾综合征的管理。
Hepatol Int. 2018 Feb;12(Suppl 1):122-134. doi: 10.1007/s12072-017-9815-0. Epub 2017 Aug 23.
10
Evaluation of eLIFT for Non-invasive Assessment of Liver fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Virus Infection.eLIFT 技术用于评估慢性乙型肝炎病毒感染患者肝纤维化和肝硬化的无创性。
Sci Rep. 2017 Jul 14;7(1):5429. doi: 10.1038/s41598-017-05718-x.

Wilson 病的肝硬化特征为肝脏合成受损、白细胞减少和血小板减少。

Cirrhosis in Wilson Disease is characterized by Impaired Hepatic Synthesis, Leukopenia and Thrombocytopenia.

机构信息

Guangdong Medical University, Zhanjiang, China.

Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.

出版信息

Int J Med Sci. 2020 May 29;17(10):1345-1350. doi: 10.7150/ijms.44338. eCollection 2020.

DOI:10.7150/ijms.44338
PMID:32624691
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7330668/
Abstract

Patients with Wilson disease (WD) progress to cirrhosis at an early age but have good prognoses. This study aimed to delineate hepatic features in WD patients with or without cirrhosis. Medical data were retrospectively collected from 27 July 2015 to 27 June 2018. WD patients were divided into two groups based on whether or not they progressed to cirrhosis. Liver function, portal hypertension features and hematocytopenia rates were compared between groups. The study enrolled 119 WD patients with cirrhosis and 53 WD patients without cirrhosis. There were no differences between groups for liver enzyme levels or incidence rates of Kayser-Fleischer ring (all > 0.05). Ascites and hepatic encephalopathy were nearly absent in both groups, and almost all patients were Child-Pugh group A. However, WD-associated cirrhotic patients had a higher prothrombin time (beta = 0.908, = 0.004) and international normalized ratio (beta = 0.089, = 0.040), wider portal vein diameter (beta = 1.330, < 0.001), and an increased risk of splenomegaly/splenectomy (odds ratio [OR] = 4.36, 95% confidence interval [CI]: 2.15-8.84, < 0.001). Moreover, WD-associated cirrhotic patients have significantly increased risks of leukopenia (OR = 2.30, 95% CI: 1.00-5.25, = 0.049) and thrombocytopenia (OR = 6.89, 95% CI: 2.01-23.59, = 0.002). Despite presenting good outcomes, mild hepatocyte injury, and good hepatic metabolic function, WD-associated cirrhotic patients show more serious impairment of hepatic synthetic function, wider portal vein diameter, and higher risk of splenomegaly due to portal hypertension.

摘要

Wilson 病(WD)患者在年轻时就会发展为肝硬化,但预后良好。本研究旨在描述 WD 患者有无肝硬化的肝脏特征。

回顾性收集 2015 年 7 月 27 日至 2018 年 6 月 27 日的医学数据。根据是否进展为肝硬化,将 WD 患者分为两组。比较两组间肝功能、门静脉高压特征和血细胞减少发生率。

研究纳入 119 例肝硬化 WD 患者和 53 例无肝硬化 WD 患者。两组间肝酶水平或凯氏环(均>0.05)发生率无差异。两组均几乎无腹水和肝性脑病,且几乎所有患者均为 Child-Pugh 分级 A。然而,WD 相关肝硬化患者的凝血酶原时间较长(β=0.908,=0.004),国际标准化比值较高(β=0.089,=0.040),门静脉直径较宽(β=1.330,<0.001),脾肿大/脾切除风险增加(比值比[OR] = 4.36,95%置信区间[CI]:2.15-8.84,<0.001)。此外,WD 相关肝硬化患者白细胞减少(OR=2.30,95%CI:1.00-5.25,=0.049)和血小板减少(OR=6.89,95%CI:2.01-23.59,=0.002)的风险显著增加。

尽管 WD 相关肝硬化患者具有良好的结局、轻度肝细胞损伤和良好的肝脏代谢功能,但肝脏合成功能更严重受损,门静脉直径更宽,门静脉高压导致脾肿大的风险更高。